-
Views
-
Cite
Cite
Phillip W. Berman, Krishna K. Murthy, Terri Wrin, Joann C. Vennari, E. Kathy Cobb, Donna J. Eastman, Mark Champe, Gerald R. Nakamura, Donna Davison, Michael F. Powell, Jeanine Bussiere, Donald P. Francis, Tom Matthews, Timothy J. Gregory, John F. Obijeski, Protection of MN-rgp120-Immunized Chimpanzees from Heterologous Infection with a Primary Isolate of Human Immunodeficiency Virus Type 1, The Journal of Infectious Diseases, Volume 173, Issue 1, January 1996, Pages 52–59, https://doi.org/10.1093/infdis/173.1.52
- Share Icon Share
Abstract
Three chimpanzees immunized with recombinant gp120 from human immunodeficiency virus type 1 (HIV-1) strain MN and 1 control animal were challenged intravenously with a primary isolate of HIV-1SF2. Viral infection was detected in the control animal by viral culture, polymerase chain reaction, and multiple serologic assays beginning 2 weeks after infection. Markers of HIV-1 infection were not detected in any of the gp120-vaccinated animals during 12 months of follow-up. Antisera from the gp120-immunized chimpanzees were unable to neutralize the challenge virus cultured in peripheral blood mononuclear cells (PBMC). These studies demonstrate that immunization with recombinant gp120derived from a T cell-adapted isolate prevented infection by a heterologous primary isolate of HIV-1. The results suggest that in vitro virus neutralization assays utilizing primary isolates cultured in PBMC may be imperfect indicators of protection in vivo.